Get Smarter on Biotech in 5 Minutes a Day.
Focused insights — expertly curated, clearly delivered, ready for action.
Get the Daily Brief
What’s in Today’s Brief? (July 20th Preview)
-
Precision oncology testing dealmaking
Tempus is set to expand its precision oncology and minimal residual disease (MRD) capabilities after signing a definitive agreement to acquire Personalis for about $1.5 billion. Under the terms, Personalis shareholders will receive $16.25 per share in Tempus stock, a roughly 6% premium, valuing the transaction at approximately $1.5 billion enterprise value, net of Tempus’ existing ownership. The companies say they have previously worked together, including a commercialization partnership for Personalis’ NeXT Personal MRD assay. Tempus expects the deal to close late this year or early next, subject to shareholder approval and regulatory clearances. Personalis also reported preliminary second-quarter revenue of $22.4 million and 10,384 clinical tests delivered, underscoring momentum in test volumes. For biopharma partners, the combination targets increased biomarker discovery and personalized cancer care through the integration of Personalis’ MRD technology with Tempus’ multimodal data and AI platform.
-
AI supercomputing commitments in pharma
Bristol Myers Squibb and Nvidia said they will expand their AI computing footprint in a move aimed at building what the companies call the most powerful “AI factory” in life sciences. BMS plans to deploy a NVIDIA DGX SuperPOD enabled with AIDGX Vera Rubin NVL72 systems, extending a collaboration that began when BMS first rolled out DGX infrastructure to support R&D three years ago. The pharma company framed the buildout as a way to increase the probability that programs selected for development are the right ones, tying the compute strategy to pipeline and operational execution. The update also positions BMS alongside other large pharma AI infrastructure efforts, as Nvidia partnerships spread across oncology and diagnostics use cases. For biotech and services providers, the announcement signals continued capital intensity around proprietary compute stacks and the operational shift from isolated pilots toward always-on data-and-model workflows.
-
Big pharma access and expansion of peptide IP/production
Samsung Biologics is moving into peptide ingredient manufacturing by planning to acquire Swiss CDMO PolyPeptide for $1.8 billion in cash. The transaction, announced Monday, would give Samsung Biologics a platform in peptide manufacturing at a time when biologics-only strategies are broadening across adjacent modalities. For PolyPeptide, the deal provides a liquidity event and potential scale benefits tied to the larger Samsung CDMO footprint. The consideration is set at $1.8 billion, and the announcement marks a notable geographic and capability expansion beyond Samsung’s core biologics process expertise. CDMOs watching the move will likely focus on how Samsung integrates peptide capabilities into its broader manufacturing network and customer offering.
-
Oncology immune engineering and clinical translation
A Johns Hopkins University team reported early clinical evidence for a KRAS-mutant peptide vaccine aimed at preventing progression in people at high risk for pancreatic ductal adenocarcinoma (PDAC). In a Phase 1 trial described in *Cancer Discovery*, researchers tested a peptide-based vaccine incorporating six common mutant KRAS (mKRAS) variations in 20 participants with genetic predisposition and confirmed pancreatic lesions. The study reported protective, antigen-specific T-cell responses and a slower progression from lesions toward cancer. Participants experienced only mild, self-resolving side effects such as fatigue and flu-like symptoms. The investigators said the immunology signals support continued development in larger trials. While the results are early and limited to a small cohort, the approach targets a defined at-risk population rather than treating PDAC after diagnosis.
-
Biotech IPO pipeline – non-opioid pain and gene medicine
Latigo Biotherapeutics outlined plans for an IPO as it prepares late-stage studies for its oral Nav1.8 inhibitor LTG-001 in a bid to compete in non-opioid pain. In IPO-related disclosures, Latigo said it intends to initiate a placebo-controlled Phase 3 trial in participants undergoing bunionectomy and an additional open-label Phase 3 safety trial across a broader mix of post-surgical and non-surgical acute pain settings, with topline results expected in the second half of 2027. The company also advances LTG-321 for osteoarthritis, with Phase 2 readouts due in the same half of 2027. Latigo’s pipeline is designed around peripheral sodium channel inhibition, targeting Nav1.8, which has already been validated by Vertex’s FDA-approved Journavx (suzetrigine). The IPO documents also set out progress, including funding accumulated since 2018 and an earlier Phase 2 completion for LTG-001. Separately, Scribe Therapeutics filed for a Nasdaq IPO to fund initial clinical development of RNA-interference style lipid-lowering genetics programs. Scribe’s planned public raise targets a Phase 1 study of STX-1150, a PCSK9 silencing candidate, plus clinical execution for APOC3 and LPA targeting assets, with early topline expectations set for later 2027.
...and 5 more selected Biotech stories in today’s full edition — or archive.
Why BioBriefs?
- Expertly curated. We scan 200+ sources daily to deliver only what matters.
- Smart context. Each brief explains why it matters and who it impacts.
- Made for pros. Trusted by founders, scientists, investors, and strategists.
Who Reads BioBriefs?
- Biotech founders & execs
- R&D and Clinical leads
- Life sciences investors
- Regulators and BD pros
- Translational scientists and tech scouts
Stay sharp. Be first to what’s next.
About BioBriefs
We’re a team of biotech analysts, technical writers, and founders who know what it’s like to scan 40 tabs and still miss what matters. BioBriefs was built to solve that. We track the signals, condense the insights, and get them to you before your day starts.